Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Docusign Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.59 (market cap $4.59B), while Docusign Inc trades at $71.55 (market cap $13.35B). The key difference: Docusign Inc is far larger — about 2.9× Definium Therapeutics Inc. Common Shares's market cap, and Docusign Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Docusign Inc for 71 Days on average.
| DFTX | DOCU | |
|---|---|---|
Market Cap | $4.59B | $13.35B |
Volume | 2,103,937 | 3,158,858 |
Sector | Health | Technology |
52-Week High | $48.45 | $73.14 |
52-Week Low | $10.68 | $41.75 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $3.55B | $12.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DOCU trades at $68.90, up 1.0% on the day, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue growth has accelerated to $2.98 billion in 2025, with net income surging to $1.07 billion. The company maintains strong profitability metrics, including a 79.49% gross margin and 17.8% ROE, while recent news highlights AI integration in contract processing and leadership in workflow software.
The outlook is supported by solid fundamentals and positive analyst sentiment, though valuation multiples like a P/E of 43.55 suggest premium pricing. Key risks include market saturation in e-signatures and insider selling activity. The consensus price target of $68.75 aligns closely with the current price, indicating a neutral near-term view with long-term growth potential from AI adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
